Skip to main content
. 2015 Sep 2;10(9):e0136324. doi: 10.1371/journal.pone.0136324

Table 5. Meta-regression analyses.

Predictors p-value
BV dosage Patient’s age Median duration of follow-up Median duration of BV therapy
PFS 0.48 0.05 0.53 0.87
OS 0.33 0.18 0.71 0.15
ORR 0.02 0.20 0.48 1.00

Abbreviations: PFS: progression free survival; OS: overall survival; ORR: overall response rate; BV: bevacizumab.